Financial Data and Key Metrics Changes - In Q1 2025, the company reported total revenues of $3,400,000, primarily from WICANT, with gross product margins around 88% [16][17] - The GAAP net loss was $9,700,000 or $0.10 per share, a significant improvement from a net loss of $20,300,000 or $0.44 per share in Q1 2024 [17] - Non-GAAP net loss for Q1 2025 was $7,800,000 or $0.08 per share, compared to $17,800,000 or $0.38 per share in the same period last year [17][18] Business Line Data and Key Metrics Changes - WICANT's dispensed applicator units increased by 16.7% over Q4 2024, surpassing 10,000 units for the first time since its launch [6][7] - Collaboration revenues totaled $17,000 in Q1 2025, related to the supply of applicators to Torii Pharmaceutical [16] Market Data and Key Metrics Changes - The company is focusing on territories with high prevalence of molluscum and has established strong insurance coverage, leading to improved sales force productivity [8][9] - The company is expanding its distribution network by adding local independent pharmacies alongside national specialty pharmacy partners [9] Company Strategy and Development Direction - The company is executing a focused commercialization strategy aimed at driving demand for WICANT, which is expected to become the standard of care for molluscum contagiosum [19] - The clinical pipeline includes advancing the phase three program for WICANT in treating common warts and the development of BP315 for basal cell carcinoma [7][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing positive feedback from healthcare professionals and improved patient access [19] - The company is exploring opportunities to strengthen its balance sheet while advancing commercial and clinical development efforts [18] Other Important Information - The company appointed Dr. Noah Rosenberg as Chief Medical Officer and Dr. Gavin Corcoran to the Board of Directors, enhancing its leadership team [13][14] Q&A Session Summary Question: Discussion on targeting pediatricians and summer demand - Management noted an increasing number of pediatricians prescribing WICANT, with marketing efforts aimed at building awareness for the treatment [22][25] Question: Conversion time between accounts receivable and revenue - The company offers sixty-day payment terms to distributors, expecting stabilization in cash conversion as inventory levels normalize [31][32] Question: Overall TAM for molluscum and coverage split - Management indicated a significant percentage of pediatric patients are covered under Medicaid, while dermatologists have a higher percentage of commercial pay [36] Question: Trends in reordering and applicators per patient - The company is seeing solid growth in customer retention and reordering, indicating positive clinician experiences with the product [42][43]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) (Exact Name of Registrant as Specified in its Charter) Delaware 46-3137900 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 44 West Gay Street, Suite 400 West Chester, PA 19380 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (484) 453-3300 N/A (Former name, former address and former fiscal year, if changed since ...

Exhibit 99.1 Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results – Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4'24 – The Company will host a conference call today, May 13 at 4:30 pm, to discuss its first quarter 2025 financial results and provide a business update. To participate in the conference call, please utilize the follow ...

Core Insights - Verrica Pharmaceuticals reported $3.4 million in revenue from YCANTH, driven by a record dispensing of over 10,000 applicator units in Q1 2025, marking a 16.7% increase from Q4 2024 [1][3][8] - The company is advancing its late-stage pipeline, including the completion of an end-of-Phase 2 meeting with the FDA for VP-315, a candidate for basal cell carcinoma, and progressing towards a global Phase 3 program for common warts (VP-102/YCANTH) in collaboration with Torii Pharmaceutical [1][3][9] Financial Performance - For Q1 2025, Verrica recognized product revenue of $3.4 million, with costs of product revenue at $0.4 million, leading to a net loss of $9.7 million or $0.10 per share, compared to a net loss of $20.3 million or $0.44 per share in Q1 2024 [12][20] - Selling, general, and administrative expenses decreased to $8.8 million from $16.3 million year-over-year, primarily due to reduced commercial activity costs [12][20] - Research and development expenses were $2.3 million in Q1 2025, down from $4.9 million in the same period last year, reflecting a decrease in clinical trial expenses for VP-315 [12][20] Business Developments - The company appointed Noah L. Rosenberg, M.D., as Chief Medical Officer, bringing extensive experience in clinical development and product launches [6][7] - Dr. Gavin Corcoran was appointed to the Board of Directors, contributing significant R&D leadership experience [7] Product Insights - YCANTH (VP-102) is the first FDA-approved treatment for molluscum contagiosum, with a strong demand reflected in the dispensing of 10,102 applicator units in Q1 2025 [8][14] - The company plans to provide additional genomic and immune response data for VP-315 in mid-2025, following a positive end-of-Phase 2 meeting with the FDA [9]

Verrica Pharmaceuticals Inc (VRCA) 2025 Conference May 07, 2025 03:00 PM ET Speaker0 Go ahead. Go ahead and get started here. So thank you everybody for joining us, this afternoon at the Citizens Life Science Conference. Excited to be joined next by Verica Pharmaceuticals. Verica is a company focused on, dermatology medicines, has an approved product for Molluscum. I've joined here this afternoon by Jason Reger, the CEO. So Jason, appreciate you being here and look forward to running through the story. Spea ...

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed to address common warts, which represent a significant unmet need in medical dermatology [3] - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Upcoming Events - The company will host a conference call and live webcast on May 13, 2025, at 4:30 p.m. ET to discuss its financial results for Q1 2025 and provide a corporate update [1] - Participants can join the call via telephone or through a live audio webcast available on the company's investor relations website [2]

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed to address common warts, which represent a significant unmet need in medical dermatology [3] - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Upcoming Event - Jayson Rieger, PhD, MBA, President and CEO of Verrica, will present at the Citizens Life Sciences Conference in New York City on May 7, 2025, at 3:00 pm ET [1][2] - Participants can access a live webcast of the event through a link provided, with a replay available for 90 days post-event [2]

– Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter – – As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue – WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases req ...

WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors. “We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors,” said Jayson Rieger, Ph.D., MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. “Gavin is a highly a ...

Shares of Verrica Pharmaceuticals Inc. (VRCA) have been struggling lately and have lost 15.3% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road. Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors. Like every technical indicator ...